Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Molecular Partners Ag (MOLN) over the last 5 years, with Q3 2025 value amounting to -$3.0 million.

  • Molecular Partners Ag's Share-based Compensation fell 2945.33% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 2055.06%. This contributed to the annual value of $4.7 million for FY2024, which is 2051.02% down from last year.
  • Per Molecular Partners Ag's latest filing, its Share-based Compensation stood at -$3.0 million for Q3 2025, which was down 2945.33% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Molecular Partners Ag's Share-based Compensation registered a high of $5.9 million during Q4 2023, and its lowest value of -$3.5 million during Q3 2023.
  • Over the past 5 years, Molecular Partners Ag's median Share-based Compensation value was $1888.8 (recorded in 2023), while the average stood at $1.1 million.
  • As far as peak fluctuations go, Molecular Partners Ag's Share-based Compensation surged by 6725.78% in 2022, and later crashed by 4819.9% in 2024.
  • Quarter analysis of 5 years shows Molecular Partners Ag's Share-based Compensation stood at $4.4 million in 2021, then grew by 19.21% to $5.3 million in 2022, then grew by 11.15% to $5.9 million in 2023, then decreased by 20.17% to $4.7 million in 2024, then tumbled by 163.18% to -$3.0 million in 2025.
  • Its Share-based Compensation was -$3.0 million in Q3 2025, compared to $2.9 million in Q2 2025 and $1270.2 in Q1 2025.